caa a22 4500 469074248 CHVBK 20180323132930.0 cr unu---uuuuu 170328e19920701xx s 000 0 eng 10.1007/BF01741793 doi (NATIONALLICENCE)springer-10.1007/BF01741793 Potential for targeting head and neck squamous cell carcinoma with monoclonal antibody K984 [Elektronische Daten] [A. Schrijvers, M. Gerretsen, M. van Walsum, B. Braakhuis, J. Quak, G. Snow, G. van Dongen] Summary: In previous reports we have described the development of mAb K984, reactive with an epitope expressed on the outer cell surface of undifferentiated, proliferating cells in normal stratified squamous epithelia and their neoplastic counterparts [28, 30]. The K984 antigen was also found to be homogeneously expressed by in vitro cultured squamous cell carcinoma (SCC) cell lines. In the present study we demonstrate that mAb K984 induces a significant, dose-dependent growth inhibition when SCC cells are grown in vitro as monolayer cultures in the presence of mAb K984. These data seem to indicate that mAb K984 has potential for tumour targeting, especially in a therapeutic setting. As a first approach to evaluate the suitability of mAb K984 for tumour targeting in vivo, radiolabelled mAb K984 was administered to SCC-xenografted nude mice. Selective tumour accumulation of mAb K984 was observed. Tumour to blood ratios and tumour to non-tumour ratios, as based on the biodistribution data, were at least ten times higher in case of the specific mAb K984 when compared to another non-specific, isotypematched control antibody. mAb K984 was also capable of visualizing tumour deposits in xenografted nude mice. The corollary of these findings is that the mAb K984-defined antigen probably is involved in the regulation of proliferation of stratified squamous epithelium and squamous cell carcinoma and that mAb K984 has potential for specific tumour targeting. Springer-Verlag, 1992 Tumour targeting nationallicence Squamous cell carcinoma nationallicence Radioimmunoconjugate nationallicence Schrijvers A. Tumour Biology Laboratory, Department of Otolaryngology, Free University Hospital, P. O. Box 7057, NL-1007 MB, Amsterdam, The Netherlands aut Gerretsen M. Tumour Biology Laboratory, Department of Otolaryngology, Free University Hospital, P. O. Box 7057, NL-1007 MB, Amsterdam, The Netherlands aut van Walsum M. Tumour Biology Laboratory, Department of Otolaryngology, Free University Hospital, P. O. Box 7057, NL-1007 MB, Amsterdam, The Netherlands aut Braakhuis B. Tumour Biology Laboratory, Department of Otolaryngology, Free University Hospital, P. O. Box 7057, NL-1007 MB, Amsterdam, The Netherlands aut Quak J. Tumour Biology Laboratory, Department of Otolaryngology, Free University Hospital, P. O. Box 7057, NL-1007 MB, Amsterdam, The Netherlands aut Snow G. Tumour Biology Laboratory, Department of Otolaryngology, Free University Hospital, P. O. Box 7057, NL-1007 MB, Amsterdam, The Netherlands aut van Dongen G. Tumour Biology Laboratory, Department of Otolaryngology, Free University Hospital, P. O. Box 7057, NL-1007 MB, Amsterdam, The Netherlands aut Cancer Immunology, Immunotherapy Springer-Verlag 34/4(1992-07-01), 252-258 0340-7004 34:4<252 1992 34 262 https://doi.org/10.1007/BF01741793 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741793 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Schrijvers A. Tumour Biology Laboratory, Department of Otolaryngology, Free University Hospital, P. O. Box 7057, NL-1007 MB, Amsterdam, The Netherlands aut NATIONALLICENCE 700 1- Gerretsen M. Tumour Biology Laboratory, Department of Otolaryngology, Free University Hospital, P. O. Box 7057, NL-1007 MB, Amsterdam, The Netherlands aut NATIONALLICENCE 700 1- van Walsum M. Tumour Biology Laboratory, Department of Otolaryngology, Free University Hospital, P. O. Box 7057, NL-1007 MB, Amsterdam, The Netherlands aut NATIONALLICENCE 700 1- Braakhuis B. Tumour Biology Laboratory, Department of Otolaryngology, Free University Hospital, P. O. Box 7057, NL-1007 MB, Amsterdam, The Netherlands aut NATIONALLICENCE 700 1- Quak J. Tumour Biology Laboratory, Department of Otolaryngology, Free University Hospital, P. O. Box 7057, NL-1007 MB, Amsterdam, The Netherlands aut NATIONALLICENCE 700 1- Snow G. Tumour Biology Laboratory, Department of Otolaryngology, Free University Hospital, P. O. Box 7057, NL-1007 MB, Amsterdam, The Netherlands aut NATIONALLICENCE 700 1- van Dongen G. Tumour Biology Laboratory, Department of Otolaryngology, Free University Hospital, P. O. Box 7057, NL-1007 MB, Amsterdam, The Netherlands aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 34/4(1992-07-01), 252-258 0340-7004 34:4<252 1992 34 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer